Welcome to our dedicated page for Longevity Health SEC filings (Ticker: XAGEW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Longevity Health Holdings, Inc. and its warrants (XAGEW) provides direct access to the company’s official regulatory disclosures. These documents explain how the business describes its focus on longevity and healthy aging, and they record key corporate and listing events affecting both the common stock and the warrants.
Through Forms 8‑K, Longevity Health Holdings reports material events such as merger agreements and terminations, reverse stock split actions, and changes in control considerations. For example, 8‑K filings detail an agreement and plan of merger with True Health Inc. and related FDA license purchase arrangements, as well as a later 8‑K stating that the True Health merger agreement was terminated when the transaction was not consummated by November 30, 2025, with no termination fee payable. Other 8‑Ks describe the merger agreement and subsequent amendment with 20/20 BioLabs, Inc., including conditions to closing and potential ownership structure of the combined company.
Filings also cover capital structure changes. A company press release and related disclosures describe a 1‑for‑30 reverse stock split of Longevity Health Holdings’ common stock, with proportional adjustments to outstanding stock options and warrants. Separate 8‑K items identify the publicly traded redeemable warrants under the symbol XAGEW and specify that each whole warrant is exercisable for one share of common stock at a stated exercise price.
Listing status is documented via Form 25 (25‑NSE) filed by Nasdaq Stock Market LLC, which identifies Longevity Health Holdings’ common stock and warrants as securities being removed from listing and/or registration under Section 12(b) of the Securities Exchange Act of 1934. This filing is the formal notice of delisting from Nasdaq for both the equity and the associated warrants.
On Stock Titan, these filings are supplemented with AI‑powered summaries that highlight the main points of each document, helping readers quickly see whether an 8‑K relates to a merger, a financing, a reverse split, or a listing change. Users can review Forms 8‑K for transaction details, Form 25 for delisting information, and other periodic reports referenced in the company’s risk factor discussions, while AI tools surface the sections most relevant to corporate actions and the structure of XAGEW warrants.
Key update: Longevity Health Holdings, Inc. (trading symbols: XAGE common shares, XAGEW warrants) filed an 8-K on 24 June 2025 announcing Amendment No. 1 to its 11 April 2025 Agreement and Plan of Merger with 20/20 Biolabs, Inc. and related parties.
Amendment terms:
- The Due Diligence Contingency Deadline is postponed from 24 June 2025 to 8 July 2025.
- If the parties do not mutually agree to another extension in writing, the entire Merger Agreement will automatically terminate on 8 July 2025.
- No other economic terms, consideration mix, or exchange ratios were modified in the filing.
Strategic context: The proposed transaction would merge Longevity Health Biomarkers, Inc. (a wholly-owned subsidiary of Longevity Health Holdings) with Biolabs, making Biolabs a wholly-owned subsidiary of the registrant. Management reiterates typical forward-looking-statement caveats and highlights numerous risks—chiefly regulatory approvals, integration challenges, Nasdaq listing maintenance, financing completion and possible cost overruns.
Investor implications:
- The short two-week extension suggests that due-diligence issues remain open but that the parties still aim to close quickly.
- Automatic termination language increases deal-completion risk and introduces a hard stop date that investors should monitor closely.
- No financial statements, pro forma data, or revised purchase price details were provided; therefore, the amendment’s direct quantitative impact cannot yet be assessed.
- The company remains an emerging growth company and smaller reporting company, so reduced disclosure requirements apply.
Overall, the filing is limited to extending a key deadline. While it keeps the deal alive, it also underscores continued uncertainties that could materially influence Longevity Health’s strategy, valuation and warrant pricing.
Longevity Health Holdings (Nasdaq: XAGE; warrants: XAGEW) filed a Form 8-K announcing Amendment No. 1 to its April 11 2025 Merger Agreement with 20/20 Biolabs.
- The amendment extends the Due Diligence Contingency Deadline to July 8 2025.
- If not further extended, the agreement will automatically terminate on July 8 2025.
- No other economic or structural terms were changed; Biolabs would become a wholly-owned subsidiary upon closing.
- Filed under Item 1.01; full text appears as Exhibit 2.1.
The report contains extensive forward-looking statements on regulatory approvals, integration, Nasdaq compliance and cost risks. Investors should watch for additional filings before the new deadline.